Table 1: Clinical and Laboratory Parameters After One Cycle of Rituximab (RTX) with Ongoing Etanercept Treatment: DAS28, IgG, IgA, IgM and Rheumatoid Factor (RF); Values Below the Normal Range are Grey (Values in % Compared to the Starting Level)
Patient 1 |
Months after RTX |
0 |
3 |
6 |
9 |
15 |
45 |
DAS28 |
5,7 |
4,4 |
4,4 |
4,8 |
3,5 |
2,13 |
IgG (690-1600 mg/dl) |
884 |
835 (94) |
671 (76) |
690 (78) |
909 (103) |
877 (99) |
IgA (70-370 mg/dl) |
283 |
250 (88) |
197 (70) |
210 (74) |
244 (86) |
301 (106) |
IgM (40-240 mg/dl) |
138 |
104 (75) |
72 (52) |
87 (63) |
76 (55) |
91 (66) |
RF (U/l) |
267 |
139 (52) |
127 (48) |
62 (23) |
54 (20) |
123 (46) |
Patient 2 |
Months after RTX |
0 |
3 |
6 |
9 |
12 |
45 |
DAS28 |
5 |
3,9 |
3,3 |
2,58 |
2,44 |
2,78 |
IgG (690-1600 mg/dl) |
1100 |
1180 (107) |
1100 (100) |
1100 (100) |
1200 (109) |
1345 (122) |
IgA (70-370 mg/dl) |
228 |
260 (114) |
246 (108) |
261 (114) |
300 (130) |
309 (135) |
IgM (40-240 mg/dl) |
66 |
59 (90) |
49 (79) |
59 (90) |
53 (80) |
48 (76) |
RF (U/l) |
174 |
131 (75) |
107 (61) |
103 (59) |
136 (78) |
172 (99) |